Inhibikase TherapeuticsIKT
13F holders, Q3 2024 (September 30)11holders −1
1new positions
2sold out
1famous investor
$1.30avg. 13F price*
At the end of Q3 2024, 11 institutions reported holding Inhibikase Therapeutics Inc. (IKT) in their 13F filings, down 1 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were Armistice Capital, LLC ($814K), Blair William & Co. ($164K) and Geode Capital Management, LLC ($65K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Inhibikase Therapeutics Inc.
- CUSIP
- 45719W205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $6K |
| Exits | 2 | $50K |
All 13F filers, Q2 2024 → Q3 2024: 64,544 shares bought and 40,808 shares sold, net +23,736 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Armistice Capital, LLC | 0.02% | Add +6.3% | 626,500 | $814K |
| Blair William & Co. | 0.00% | Add +8.6% | 126,120 | $164K |
| Geode Capital Management, LLC | 0.00% | Add +34.1% | 50,065 | $65K |
| Renaissance Technologies | 0.00% | Reduce -4.3% | 19,922 | $26K |
| Vanguard Group Inc. | 0.00% | No change | 16,724 | $22K |
| State Street Corp. | 0.00% | No change | 10,084 | $13K |
| UBS Group AG | 0.00% | New | 4,873 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -29.3% | 4,057 | $5K |
| Morgan Stanley | 0.00% | No change | 1,667 | $2K |
| Wells Fargo & Company | 0.00% | No change | 167 | $217 |
| Bank of America Corp. | 0.00% | Add +26.2% | 53 | $69 |
"% of holder's portfolio" is IKT's weight in each manager's 13F, not the share of Inhibikase Therapeutics Inc. the manager owns.